Trends in pharmacy-based dispensing of buprenorphine, extended-release naltrexone, and naloxone during the COVID-19 pandemic by age and sex – United States, March 2019 – December 2020

•Declines in extended-release naltrexone dispensing may indicate reduced access.•Despite increases in buprenorphine and naloxone, there may not be adequate access.•Expanding treatment access is crucial during and after the pandemic.•There are several policies, such as telehealth, that can help increase access.